Table 2.

Correlation of PRDX mRNA expression with clinical stages of lung cancer patients

Gene	Clinical stages	HR (95% CI)	Log rank P
PRDX1	I	1.7 (1.29–2.24)	0.0002*
	II	1.39 (0.96–2)	0.0812
	III	1.04 (0.6–1.79)	0.8903
PRDX2	I	2.03 (1.51–2.71)	1.3e–06*
	II	1.06 (0.73–1.53)	0.753
	III	1.04 (0.6–1.8)	0.8863
PRDX3	I	0.73 (0.56–0.95)	0.0218*
	II	0.72 (0.5–1.04)	0.0782
	III	1.16 (0.67–1.99)	0.6013
PRDX4	I	1.09 (0.83–1.43)	0.5287
	II	0.81 (0.56–1.17)	0.2608
	III	0.95 (0.55–1.65)	0.8551
PRDX5	I	0.77 (0.56–1.05)	0.0975
	II	0.97 (0.62–1.52)	0.8819
	III	1.04 (0.5–2.17)	0.9078
PRDX6	I	0.59 (0.45–0.77)	0.00013*
	II	0.6 (0.42–0.87)	0.0063*
	III	1.01 (0.59–1.73)	0.9748

Note:

^*P<0.05.

Abbreviation: PRDX, peroxiredoxin.